We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is de... Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. Show more
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing...
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.01 | 0.675675675676 | 1.48 | 1.54 | 1.37 | 216634 | 1.41225797 | CS |
4 | -0.21 | -12.3529411765 | 1.7 | 1.81 | 1.37 | 230690 | 1.60225426 | CS |
12 | 0.13 | 9.55882352941 | 1.36 | 1.89 | 1.33 | 336770 | 1.65513394 | CS |
26 | 0.5 | 50.5050505051 | 0.99 | 1.89 | 0.99 | 248898 | 1.53329501 | CS |
52 | -0.2 | -11.8343195266 | 1.69 | 1.995 | 0.99 | 273876 | 1.52308838 | CS |
156 | -12.09 | -89.027982327 | 13.58 | 19.87 | 0.6801 | 959954 | 2.35768391 | CS |
260 | -10.73 | -87.8068739771 | 12.22 | 23.639 | 0.6801 | 641752 | 3.55648262 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions